10 Firms End 2024 Stronger With Impressive Gains

Page 9 of 9

1. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Shares in ACADIA Pharmaceuticals increased by 9.95 percent on Wednesday, finishing the year higher at $18.35 apiece following news that it is set to join the S&P SmallCap 600 effective Friday, January 3, 2025, replacing Independent Bank Group Inc.

The S&P 600 is a stock market index tracking the performance of 600 small-cap companies in the US. It is designed to be a reliable benchmark for investors and traders and represents about 3 percent of the US market.

Year-to-date, however, registered a plunge of 40 percent from its valuation a year ago.

Acadia Pharmaceuticals is a biopharmaceutical company specializing in innovative treatments for central nervous system (CNS) disorders including Parkinson’s disease psychosis, Alzheimer ’s-related psychosis, schizophrenia, and Rett syndrome.

It owns NUPLAZID, an FDA-approved treatment for Parkinson’s psychosis. Acadia’s robust research and development pipeline focuses on the growing needs in neurology and psychiatry.

While we acknowledge the potential of ACAD as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ACAD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9